CSSH-1
CSSH-3
CSSH-2

product

more>>

about us

dfgdf

what we do

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000. On 19 August 2011, the company was listed on the Growth Enterprise Market of Shenzhen Stock Exchange (stock code 300255). The company has four production bases, nine subsidiaries, two overseas companies, and two joint ventures. The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade. It is a key high-tech enterprise with products from heparin crude products to low molecular weight heparin injections and a complete heparin industrial chain in the field of heparin, and a leading pharmaceutical company in the production of domestic heparin products.

more>>
Quality policy

Quality of survival, management for efficiency, integrity and reputation, innovation and development.

more>>
  • Always puts the quality at the first place and strictly supervise the product quality of every process.

    Quality

    Always puts the quality at the first place and strictly supervise the product quality of every process.

  • Our Factory has grown into a Premier  Certified manufacturer of High quality, Cost-Effective products

    Certificate

    Our Factory has grown into a Premier Certified manufacturer of High quality, Cost-Effective products

  • The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

    Manufacturer

    The company is a biochemical pharmaceutical enterprise, integrating research and development, production, sales, and import and export trade

Exhibition Style

  • Team 796

    Team

  • Founded Time September 28, 2000

    Founded Time

  • Number of patents 11

    Number of patents

  • Total exports in 2019 68 million dollars

    Total exports in 2019

news

Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000.

CSBIO Fight the epidemic while speeding up production

The “Recommendations for the Prevention and Treatment of Venous Thromboembolism Related to Novel Coronavirus Pneumonia” pointed out: Nearly 20% of patients with new coronary disease will have coagulation abnormalities, and almost all severe and critical patients have coagulation disor...
more>>

Two misunderstandings of heparin-induced thrombocytopenia

Changshan Medical News Heparin-induced thrombocytopenia (HIT) is a complication characterized by thrombocytopenia caused by heparin, which mainly manifests as thrombocytopenia, platelet activation or thrombosis. There are two clinical types, one is with thrombosis, and the other is only antibody ...
more>>

Are Thrombotic superficial phlebitis(STP)Also a kind of venous thrombosis?

Superficial thrombophlebitis (STP), also known as superficial vein thrombosis, is an inflammatory reaction in the lumen of the superficial vein, accompanied by thrombosis. Epidemiological data show that the incidence of STP is about 3% to 11% [1]. The disease is more common in women. The ratio of...
more>>

Anticoagulant effect of low molecular weight heparin on new coronary pneumonia

1.Diagnosis and Treatment for COVID-19 (Trial version 8) by National Health Commission of the P.R.C. The risk of thromboembolism is higher in severe or critical patients,……, Anticoagulants should be used prophylactically. In case of thromboembolism, anticoagulant therapy should be car...
more>>

Announcement that the Hebei Changshan’s bovine source heparin products have obtained Halal certification

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) bovine source heparin sodium raw materials and heparin sodium injection passed the Shandong Halal Certification Service Co., Ltd. (SHC) on-site audit according to MUI HAS23000 and MS1500:20...
more>>